Wisconsin Jails and Prisons Double Access to Opioid Treatment Medications in Four Years

Wisconsin's county jails and state prisons have more than doubled the availability of medications for opioid use disorder over the past four years, a transformation documented in a new Wisconsin Policy Forum report released this week. The expansion comes as the state has seen overdose deaths drop substantially from their 2022 peak, though officials caution that opioid addiction remains one of Wisconsin's most serious public health challenges.

In 2021, just 41% of Wisconsin county jails provided access to at least one type of medication for opioid use disorder. By late 2025, that figure had jumped to 81.5%, according to survey findings from the nonpartisan research organization. The increase is even more dramatic in state corrections facilities: all 36 Wisconsin Department of Corrections facilities now provide some form of medication access, up from just 13 of 35 facilities in 2021.

The number of individuals receiving these medications in state prisons has increased more than sixfold—from 48 people in 2021 to 302 in 2024.

Lives Saved Behind Bars and Beyond

Medications for opioid use disorder—primarily buprenorphine, methadone, and naltrexone—help people manage withdrawal symptoms and reduce cravings. Research has consistently shown that providing these medications to incarcerated individuals dramatically reduces their risk of overdose death after release, a particularly dangerous period when tolerance has declined during forced abstinence.

The Wisconsin Policy Forum surveyed all 71 county jails in late 2025, receiving complete responses from 58 facilities and abbreviated responses from seven more. Together, these 65 counties account for 97% of the state's jail population.

"Given the magnitude of these changes and the other available research, it is reasonable to think these practices have likely improved health and potentially even saved lives across the state," the report concludes.

Jason Stein, president of the Wisconsin Policy Forum, noted that while opioid deaths have dropped noticeably since 2024, the number of overdose deaths statewide remains slightly higher than motor vehicle fatalities. Between 2016 and 2023, more than 9,000 Wisconsinites died from opioid overdoses. Deaths peaked at over 1,500 in a twelve-month period around 2022 but had fallen by more than 900 by September 2025.

Methadone Access Expands, But Gaps Remain

The report reveals particularly striking growth in methadone availability. In 2021, only three county jails provided access to methadone, widely considered the gold standard for treating severe opioid addiction. By 2025, that number had increased to 24 facilities.

All state prisons now also provide naloxone—the overdose-reversal medication—to individuals with a history of substance use when they leave prison. In 2021, no state prisons offered this life-saving intervention.

Despite the progress, significant access gaps persist. At least eight county jails, mostly in small and rural counties, still do not provide any access to medications for opioid use disorder. Five additional jails did not respond to the survey. Among the 47 county jails that answered questions about initiating treatment, 16 said they do not start people on opioid medications even if clinical need is identified.

Most state corrections facilities continue to limit medication access to individuals who arrive already prescribed buprenorphine or naltrexone, rather than initiating new treatment during incarceration. Different jails maintain different policies regarding who qualifies to receive these medications, creating a patchwork system where access depends heavily on which facility someone enters.

Federal Pressure and Settlement Funds Drive Change

The expansion appears driven by multiple factors. The U.S. Department of Justice has stated that jails are required to provide medications for opioid use disorder under the Americans with Disabilities Act, a legal interpretation that has prompted policy reviews in correctional systems nationwide.

Professional medical organizations including the American Society of Addiction Medicine have also urged facilities to offer these medications, pointing to the strong evidence base showing their effectiveness in reducing overdose deaths and recidivism.

Funding from opioid lawsuit settlements has likely played a critical role as well, providing resources that cash-strapped county jails could deploy to cover startup costs for medication programs, staff training, and ongoing operations. Wisconsin is among more than a dozen states receiving portions of over $50 billion in settlements with pharmaceutical companies over their role in fueling the opioid crisis.

Implementation Challenges in Rural Counties

For county jails, particularly those in rural areas, decisions about expanding access involve navigating complex tradeoffs. Facilities must balance the clinical benefits of medication access against the cost and staffing requirements involved in administering and monitoring these programs.

The report suggests that counties wishing to expand access might achieve efficiencies by building or expanding regional teams of substance use and opioid treatment specialists, potentially collaborating with neighboring counties, state corrections institutions, or private vendors. Opioid settlement funds could help offset these costs.

The survey did not detail why some facilities continue to resist providing medication access, but past resistance in correctional settings has often stemmed from misunderstandings about these medications—particularly concerns about "substituting one addiction for another"—despite extensive research showing they reduce mortality and support recovery without producing euphoria when used as prescribed.

A Model Taking Hold Nationally

Wisconsin's experience mirrors a broader shift in corrections policy across the United States. A national survey published earlier this month found that 58% of jails, prisons, and detention centers now offer at least one FDA-approved medication for opioid use disorder, though significant regional disparities persist.

The Wisconsin Policy Forum report was commissioned by Vital Strategies, a global nonprofit public health organization working to strengthen evidence-based solutions to reduce overdose deaths in Wisconsin and other U.S. states.

The Forum itself is Wisconsin's leading source of nonpartisan, independent research on state and local public policy, supported by hundreds of corporations, nonprofits, local governments, school districts, and individuals.

Whether Wisconsin's expansion continues or stalls may depend on sustained political will, continued access to settlement funding, and the willingness of correctional administrators to view medication-based treatment as a public health intervention rather than a security threat. The data suggest that when facilities remove barriers to medication access, lives are saved—both inside correctional walls and in the critical weeks after release, when the risk of fatal overdose peaks.

As overdose deaths continue to fall across Wisconsin and much of the nation, the question is no longer whether these medications work. It's whether every county, every jail, and every prison will implement the evidence-based practices that could prevent the next preventable death.